Blar i Bergen Open Research Archive på forfatter "Wulf, Gerburg M."
-
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers
Batalini, Felipe; Gulhan, Doga C.; Mao, Victor; Tran, Antuan; Polak, Madeline; Xiong, Niya; Tayob, Nabihah; Tung, Nadine M.; Winer, Eric P.; Mayer, Erica L.; Knappskog, Stian; Lønning, Per Eystein; Matulonis, Ursula A.; Konstantinopoulos, Panagiotis A.; Solit, David B.; Won, Helen; Eikesdal, Hans Petter; Park, Peter J.; Wulf, Gerburg M. (Journal article; Peer reviewed, 2022)Purpose: The identification of patients with homologous recombination deficiency (HRD) beyond BRCA1/2 mutations is an urgent task, as they may benefit from PARP inhibitors. We have previously developed a method to detect ... -
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype
Wang, Lin; Wang, Dan; Sonzogni, Olmo; Ke, Shizhong; Wang, Qi; Thavamani, Abhishek; Batalini, Felipe; Stopka, Sylwia A.; Regan, Michael S.; Vandal, Steven; Tian, Shengya; Pinto, Jocelin; Cyr, Andrew M.; Bret-Mounet, Vanessa C.; Baquer, Gerard; Eikesdal, Hans Petter; Yuan, Min; Asara, John M.; Heng, Yujing J.; Bai, Peter; Agar, Nathalie Y.R.; Wulf, Gerburg M. (Journal article; Peer reviewed, 2022)Poly(ADP)ribosylation inhibitors (PARPis) are toxic to cancer cells with homologous recombination (HR) deficiency but not to HR-proficient cells in the tumor microenvironment (TME), including tumor-associated macrophages ...